Abbott Laboratories (ABT)

Cash ratio

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Cash and cash equivalents US$ in thousands 7,511,000 6,951,000 6,532,000 7,616,000 7,558,000 6,987,000 6,284,000 6,896,000 6,709,000 7,835,000 9,882,000 9,882,000 9,594,000 8,937,000 7,675,000 9,799,000 9,302,000 8,658,000 8,054,000 6,838,000
Short-term investments US$ in thousands 222,000 331,000 312,000 351,000 230,000 232,000 367,000 383,000 338,000 320,000 288,000 288,000 313,000 353,000 483,000 450,000 390,000 286,000 318,000 310,000
Total current liabilities US$ in thousands 14,582,000 13,439,000 13,004,000 14,157,000 14,902,000 13,760,000 14,021,000 13,841,000 13,042,000 14,350,000 15,489,000 15,489,000 13,365,000 12,392,000 12,647,000 13,105,000 12,867,000 12,614,000 12,462,000 11,907,000
Cash ratio 0.53 0.54 0.53 0.56 0.52 0.52 0.47 0.53 0.54 0.57 0.66 0.66 0.74 0.75 0.65 0.78 0.75 0.71 0.67 0.60

September 30, 2025 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($7,511,000K + $222,000K) ÷ $14,582,000K
= 0.53


See also:

Abbott Laboratories Cash Ratio (Quarterly Data)